Efficacy of Intravenous Methoxy Polyethylene Glycol-Epoetin Beta Administered Every 2 Weeks Compared With Epoetin Administered 3 Times Weekly in Patients Treated by Hemodialysis or Peritoneal Dialysis: A Randomized Trial

医学 血液透析 人口 内科学 肾脏疾病 透析 促红细胞生成素 贫血 腹膜透析 胃肠病学 随机对照试验 血红蛋白 外科 泌尿科 环境卫生
作者
Marian Klinger,Manual Arias,Vassilis Vargemezis,Anatole Besarab,Władysław Sułowicz,Trevor Gerntholtz,Kazimierz Ciechanowski,Frank C. Dougherty,Ulrich Beyer
出处
期刊:American Journal of Kidney Diseases [Elsevier BV]
卷期号:50 (6): 989-1000 被引量:74
标识
DOI:10.1053/j.ajkd.2007.08.013
摘要

Background C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin receptor activator, was developed to provide stable control of hemoglobin (Hb) levels at extended administration intervals in patients with chronic kidney disease. We examined its efficacy for Hb level correction when administered once every 2 weeks in erythropoiesis-stimulating agent–naive dialysis patients. Study Design Open-label, multicenter, randomized, parallel-group, phase 3 study. Setting & Participants Dialysis patients (age ≥ 18 years). Intervention Patients (n = 181) were randomly assigned (3:1) to receive intravenous C.E.R.A. once every 2 weeks or epoetin 3 times weekly. Outcomes & Measurements The primary end point was Hb level response rate (increase in Hb level ≥ 1 g/dL [10 g/L] versus baseline and Hb level ≥ 11 g/dL [110 g/L] without blood transfusion during the 24-week correction period) in the intent-to-treat population. Results Hb response rates (intent-to-treat population) were 93.3% with C.E.R.A. and 91.3% with epoetin. Similar results were found in the per-protocol population. Peak mean Hb levels were 12.28 ± 1.13 (SD) g/dL (122.8 ± 11.3 g/L) with C.E.R.A. and 12.19 ± 1.24 g/dL (121.9 ± 12.4 g/L) with epoetin. Mean change in Hb levels from baseline to the end of the correction period were 2.70 ± 1.45 g/dL (27 ± 14.5 g/L) with C.E.R.A. and 2.56 ± 1.31 g/dL (25.6 ± 13.1 g/L) with epoetin. Both treatments were generally well tolerated. Limitations Open-label study design, 3:1 randomization, limited peritoneal dialysis population, descriptive statistics, and lack of formal prespecified comparison to epoetin. Conclusions Intravenous C.E.R.A. once every 2 weeks may be as safe and effective as 3-times-weekly epoetin for correcting anemia in dialysis patients. These results show the utility of intravenous C.E.R.A. administered once every 2 weeks in erythropoiesis-stimulating agent–naive dialysis patients. C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin receptor activator, was developed to provide stable control of hemoglobin (Hb) levels at extended administration intervals in patients with chronic kidney disease. We examined its efficacy for Hb level correction when administered once every 2 weeks in erythropoiesis-stimulating agent–naive dialysis patients. Open-label, multicenter, randomized, parallel-group, phase 3 study. Dialysis patients (age ≥ 18 years). Patients (n = 181) were randomly assigned (3:1) to receive intravenous C.E.R.A. once every 2 weeks or epoetin 3 times weekly. The primary end point was Hb level response rate (increase in Hb level ≥ 1 g/dL [10 g/L] versus baseline and Hb level ≥ 11 g/dL [110 g/L] without blood transfusion during the 24-week correction period) in the intent-to-treat population. Hb response rates (intent-to-treat population) were 93.3% with C.E.R.A. and 91.3% with epoetin. Similar results were found in the per-protocol population. Peak mean Hb levels were 12.28 ± 1.13 (SD) g/dL (122.8 ± 11.3 g/L) with C.E.R.A. and 12.19 ± 1.24 g/dL (121.9 ± 12.4 g/L) with epoetin. Mean change in Hb levels from baseline to the end of the correction period were 2.70 ± 1.45 g/dL (27 ± 14.5 g/L) with C.E.R.A. and 2.56 ± 1.31 g/dL (25.6 ± 13.1 g/L) with epoetin. Both treatments were generally well tolerated. Open-label study design, 3:1 randomization, limited peritoneal dialysis population, descriptive statistics, and lack of formal prespecified comparison to epoetin. Intravenous C.E.R.A. once every 2 weeks may be as safe and effective as 3-times-weekly epoetin for correcting anemia in dialysis patients. These results show the utility of intravenous C.E.R.A. administered once every 2 weeks in erythropoiesis-stimulating agent–naive dialysis patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
2秒前
2秒前
TaoJ给虚幻的蛋挞的求助进行了留言
2秒前
n01W97的应助被minmi采纳,获得20
3秒前
3秒前
玉龙完成签到,获得积分10
3秒前
领导范儿的应助被冰冰采纳,获得10
4秒前
李爱国的应助被fifteen采纳,获得10
5秒前
ff06发布了新的文献求助10
5秒前
5秒前
zxy完成签到,获得积分10
7秒前
lzh发布了新的文献求助10
7秒前
小白完成签到,获得积分10
8秒前
hajimi完成签到 ,获得积分10
8秒前
9秒前
9秒前
曙光完成签到,获得积分20
11秒前
minmi完成签到,获得积分10
12秒前
12秒前
13秒前
13秒前
14秒前
初景发布了新的文献求助10
14秒前
枯蚀完成签到,获得积分10
14秒前
15秒前
xiaoming发布了新的文献求助10
15秒前
眯眯眼的太阳完成签到 ,获得积分10
15秒前
15秒前
CAOHOU的应助被曙光采纳,获得10
16秒前
16秒前
17秒前
17秒前
17秒前
18秒前
zo发布了新的文献求助10
18秒前
18秒前
灵熙发布了新的文献求助10
19秒前
风吹麦浪发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183694
求助须知:如何正确求助?哪些是违规求助? 9572963
关于积分的说明 21828306
捐赠科研通 7780864
什么是DOI,文献DOI怎么找? 3434057
关于科研通互助平台的介绍 2558257
邀请新用户注册赠送积分活动 2480541